Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 3, 2012, Pages 160-169

  Minematsu, Tsuyoshi ^a   Sonoda, Takuya ^a   Hashimoto, Tadashi ^a   Iwai, Megumi ^a   Oppeneer, Todd ^b   Felder, Laurie ^b   Shirai, Nobuaki ^c   Miyashita, Aiji ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b 206 Carnegie Center   (United States)

^c Nemoto Science Co Ltd   (Japan)

Author keywords

distribution; excretion; pharmacokinetics; rat; YM155

Indexed keywords

CARBON 14; SEPANTRONIUM BROMIDE; SURVIVIN;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; ISOTOPE LABELING; LACTATION; MALE; NONHUMAN; PREGNANCY; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE; BLOOD PROTEINS; FECES; FEMALE; IMIDAZOLES; LACTATION; MALE; MATERNAL-FETAL EXCHANGE; MICROTUBULE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; PLACENTA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84859716777     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1781     Document Type: Article

References (27)

1. Giodini A, Kallio MJ, Wall NR, et al,. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62: 2462-2467. (Pubitemid 34462718)
2. O'Connor DS, Grossman D, Plescia J, et al,. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-13107.
3. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921. (Pubitemid 27353455)
4. Nakahara T, Takeuchi M, Kinoyama I, et al,. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021. (Pubitemid 47395135)
5. Nakahara T, Kita A, Yamanaka K, et al,. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011; 102: 614-621.
6. Tolcher AW, Mita A, Lewis LD, et al,. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-5203.
7. Giaccone G, Zatloukal P, Roubec J, et al,. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
8. Minematsu T, Felder L, Oppeneer T, et al,. Liquid chromatography- electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma. Biomed Chromatogr 2008; 22: 763-769.
9. Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T,. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab Dispos 2011; 39: 2314-2320.
10. Iwai M, Minematsu T, Narikawa S, Usui T, Kamimura H,. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)- 2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d] imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos 2009; 37: 1856-1863.
11. Minematsu T, Iwai M, Sugimoto K, et al,. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 2009; 37: 619-628.
12. Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H,. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 2010; 38: 1-4.
13. Minematsu T, Hashimoto T, Aoki T, Usui T, Kamimura H,. Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. Drug Metab Dispos 2008; 36: 1496-1504.
14. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)
15. Sohda K, Suzuki K, Nakamura E, et al,. Metabolism of YM155 monobromide, a novel survivin suppressant: in vitro species comparison and identification of metabolites in rats. Drug Metab Rev 2007; 39 (Suppl 1): 253.
16. Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, Klaassen CD,. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos 2002; 30: 212-219. (Pubitemid 34106542)
17. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H,. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549-552. (Pubitemid 24368536)
18. Koepsell H, Lips K, Volk C,. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251. (Pubitemid 46876495)
19. Nakanishi T, Haruta T, Shirasaka Y, Tamai I,. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos 2011; 39: 117-122.
20. Tahara H, Kusuhara H, Endou H, et al,. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 2005; 315: 337-345. (Pubitemid 41380529)
21. Dresser MJ, Gray AT, Giacomini KM,. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther 2000; 292: 1146-1152. (Pubitemid 30136612)
22. Leazer TM, Klaassen CD,. The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos 2003; 31: 153-167. (Pubitemid 36159607)
23. Ushigome F, Koyabu N, Satoh S, et al,. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm Res 2003; 20: 38-44. (Pubitemid 36152915)
24. Jonker JW, Merino G, Musters S, et al,. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11: 127-129. (Pubitemid 40321346)
25. Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ,. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J Pharmacol Exp Ther 2001; 296: 175-180. (Pubitemid 32015076)
26. Ito S, Alcorn J,. Xenobiotic transporter expression and function in the human mammary gland. Adv Drug Deliv Rev 2003; 55: 653-665. (Pubitemid 36428678)
27. Arimori K, Nakano M,. Drug exsorption from blood into the gastrointestinal tract. Pharm Res 1998; 15: 371-376. (Pubitemid 28186980)